MeiraGTx Holdings plc. (3/6/19). "Press Release: MeiraGTx to Present at the Barclays Global Healthcare Conference". London & New York, NY.

	Region	Miami, FL
	Country	United States (USA)
	Organisation	MeiraGTx Holdings Plc (NASDAQ: MGTX)
	Group	MeiraGTx (Group)
	Organisation 2	Barclays (Group)
	Product	Barclays Global Healthcare Conference 2019 Miami
	Product 2	gene therapy
	Index term	MeiraGTx–Barclays: investor conference, 201903 supply service MeiraGTx presents at Barclays Global Healthcare Conference
	Person	Forbes, Alexandria (MeiraGTx 201810 CEO)
	Person 2	Pascale, Christiana (W2O Group 201901 at W2O pure)

MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 12, 2019, at 2:35 p.m. EST.

A live webcast of MeiraGTx’s presentation and the accompanying presentation materials will be available from the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for 30 days following the presentation.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with five programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Elizabeth Broder
(646) 860-7983
Investors@meiragtx.com

or

Media:
W2O pure
Christiana Pascale
(212) 267-6722
cpascale@purecommunications.com

Record changed: 2023-06-05